Trade Fulgent Genetics, Inc. - FLGT CFD

Fulgent Genetics, Inc. Company profile

Fulgent Genetics (FLGT) is a global molecular diagnostic and genetic testing services provider. 

Headquartered in Temple City, California, Fulgent Genetics was founded in 2011 as Fulgent Diagnostics. The company merges the fields of genetics, molecular biology and computer science to conduct diagnostic testing and genomic sequencing.It offers flexible testing options for physicians and patients. 

Fulgent Genetics’ portfolio consists of more than 18,000 single genes for genetic testing, 800 rare disease tests, complete genome sequencing, complete genome Copy Number Variation (CNVs) analysis, mitochondrial sequencing and CLIA/CAP quality sequencing services.

The company has received accreditations from the Clinical Laboratory Improvement Amendments (CLIA), the College of American Pathologists (CAP), the California Clinical Laboratory, the Pennsylvania Clinical Laboratory, the Maryland Medical Laboratory, the New York State Clinical Laboratory and the Rhode Island Laboratory. Its strategic partnership with Helio Health aims to help the company commercialise tests for blood-based early cancer detection. 

Fulgent Genetics Inc. stock began trading on the NASDAQ in 2016 under the ticker symbol FLGT. 

You can track the FLGT share value and price history live at capital.com.